Rare cancers (those with an incidence rate of <6 per 100,000 persons per year) comprise 198 varieties and are primarily grouped according to their site of origin. Collectively, they represent 24% of all cancer diagnoses and are under-researched due to underfunding, their complexities, and challenges in conducting traditional clinical designs used in common cancers.
This session, chaired by Professor Richard Wilson from the University of Glasgow, will demonstrate the great progress that has been made recently in rare cancer research. Biliary tract cancer can now be treated using personalized medicine approaches based on underlying genomic aberrations in eg FGFR2 fusions and mutations in IDH and DDR genes. Small bowel adenocarcinoma is now understood to have different genetic drivers than gastric and colorectal cancer and updates on this and therapeutic approaches will be given. Finally, a more general overview of genomic profiling and its use in early and late phase trials in rare cancers will be discussed.
- Dr Mairéad Mcnamara – University of Manchester/The Christie NHS Foundation Trust, UK
- Professor Michael Overman – The University of Texas, USA
- Professor Thomas Aparicio – Saint Louis Hospital, France
1 category 1 (external) CPD for this session has been approved by the Federation of the Royal Colleges of Physicians. CPD Certificates will be sent to delegates automatically up to 10 days after the event date.
Who should attend?
Scientists, medical/clinical oncologists, surgeons, early career researchers, nurses, allied health professionals, PhD and undergraduate students, research teams, research managers/funders, patient experts and carers (formally involved in research) – who have an interest in rare cancers.